Cannabis firm Trulieve posts wider Q3 net loss

Trulieve Cannabis

05/11/2025 11:22

Overview

Trulieve Q3 revenue rises 1% yr/yr to $288 mln, with 59% gross margin

Company reports Q3 net loss of $27 mln, adjusted net loss of $12 mln

Trulieve generated $77 mln in cash flow from operations in Q3

Result Drivers

RETAIL SALES - 94% of Q3 revenue came from retail sales, contributing significantly to overall performance

NEW PRODUCT LAUNCHES - Launched new Roll One Clutch All In One vapes in Florida, selling out in under two weeks

LOYALTY PROGRAM - 77% of transactions in Q3 were from loyalty program members, enhancing customer retention

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$288 mln
Q3 Adjusted EPS
-$0.07
Q3 EPS
-$0.11
Q3 Adjusted Net Income
-$12 mln
Q3 Net Income
-$27 mln
Q3 Adjusted EBITDA
$103 mln
Q3 Gross Margin
59%
Q3 Gross Profit
$170 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Trulieve Cannabis Corp is C$17.00, about 45.2% above its November 4 closing price of C$9.32

Press Release: ID:nCNWvMykJa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)